Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C10H15N3O.ClH |
Molecular Weight | 229.707 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.[H][C@@]1(CN2CCC1CC2)C(\C#N)=N\OC
InChI
InChIKey=INJWRVWKJFJRFO-SCRZZQONSA-N
InChI=1S/C10H15N3O.ClH/c1-14-12-10(6-11)9-7-13-4-2-8(9)3-5-13;/h8-9H,2-5,7H2,1H3;1H/b12-10+;/t9-;/m0./s1
Molecular Formula | C10H15N3O |
Molecular Weight | 193.2456 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 1 |
Optical Activity | UNSPECIFIED |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Sabcomeline (SB-202026) is a potent and functionally selective M1 receptor partial agonist that originally was developed by GlaxoSmithKline. Sabcomeline had been in phase III clinical trials for the treatment of Alzheimer's disease and phase II for schizophrenia and major depressive disorder. In addition, it was studied for patients with Type 2 diabetes mellitus. However, due to poor results, the development of this drug was discontinued.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
SB 202026: a novel muscarinic partial agonist with functional selectivity for M1 receptors. | 1997 Dec |
|
Design of [R-(Z)]-(+)-alpha-(methoxyimino)-1-azabicyclo[2.2.2]octane-3-acetonitri le (SB 202026), a functionally selective azabicyclic muscarinic M1 agonist incorporating the N-methoxy imidoyl nitrile group as a novel ester bioisostere. | 1997 Dec 19 |
|
Sabcomeline (SB-202026), a functionally selective M1 receptor partial agonist, reverses delay-induced deficits in the T-maze. | 1998 Aug |
|
The profile of sabcomeline (SB-202026), a functionally selective M1 receptor partial agonist, in the marmoset. | 1998 May |
|
Low-affinity M(2) receptor binding state mediates mouse atrial bradycardia: comparative effects of carbamylcholine and the M(1) receptor agonists sabcomeline and xanomeline. | 2001 Mar |
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:34:51 GMT 2023
by
admin
on
Fri Dec 15 15:34:51 GMT 2023
|
Record UNII |
A24BK93DRR
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C47796
Created by
admin on Fri Dec 15 15:34:51 GMT 2023 , Edited by admin on Fri Dec 15 15:34:51 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
A24BK93DRR
Created by
admin on Fri Dec 15 15:34:51 GMT 2023 , Edited by admin on Fri Dec 15 15:34:51 GMT 2023
|
PRIMARY | |||
|
159912-58-0
Created by
admin on Fri Dec 15 15:34:51 GMT 2023 , Edited by admin on Fri Dec 15 15:34:51 GMT 2023
|
PRIMARY | |||
|
9577994
Created by
admin on Fri Dec 15 15:34:51 GMT 2023 , Edited by admin on Fri Dec 15 15:34:51 GMT 2023
|
PRIMARY | |||
|
CHEMBL134641
Created by
admin on Fri Dec 15 15:34:51 GMT 2023 , Edited by admin on Fri Dec 15 15:34:51 GMT 2023
|
PRIMARY | |||
|
m9714
Created by
admin on Fri Dec 15 15:34:51 GMT 2023 , Edited by admin on Fri Dec 15 15:34:51 GMT 2023
|
PRIMARY | Merck Index | ||
|
JJ-70
Created by
admin on Fri Dec 15 15:34:51 GMT 2023 , Edited by admin on Fri Dec 15 15:34:51 GMT 2023
|
PRIMARY | |||
|
C152279
Created by
admin on Fri Dec 15 15:34:51 GMT 2023 , Edited by admin on Fri Dec 15 15:34:51 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |